Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFRT790M-Mutated NSCLC That Had Progressed After Prior EGFRTyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
- Resource Type
- Article
- Source
- Journal of Thoracic Oncology; October 2022, Vol. 17 Issue: 10 p1192-1204, 13p
- Subject
- Language
- ISSN
- 15560864; 15561380